| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Inflammatory pathways (NO production); antimicrobial targets. N-Phenethylbenzamide inhibits LPS-induced NO production in RAW264.7 cells with an IC₅₀ of >50 μM. Its anti-inflammatory mechanism involves inhibition of inducible nitric oxide synthase (iNOS) expression or activity. The compound exhibits antimicrobial activity against Gram-positive and Gram-negative bacteria, including MRSA and VRE. Its neuroprotective and spasmolytic activities suggest interactions with neurological and smooth muscle targets.
|
|---|---|
| ln Vitro |
At an IC50 value of less than 50 μM, N-phenethylbenzamide suppresses the production of NO induced by LPS[1].
N-Phenethylbenzamide inhibits LPS-induced NO production in RAW264.7 cells with an IC₅₀ of >50 μM. It exhibits anti-inflammatory, analgesic, and anticancer properties. The compound also shows neuroprotective and spasmolytic activities and has demonstrated efficacy against MRSA and VRE. It can interact with various cellular pathways, making it useful in drug development for pain, inflammation, and cancer. |
| ln Vivo |
In vivo studies of N-phenethylbenzamide are limited. As an anti-inflammatory compound that inhibits NO production, it has potential for evaluation in animal models of inflammation. Its antimicrobial activity against MRSA and VRE suggests potential for evaluation in infection models. Its neuroprotective and spasmolytic activities suggest potential benefits in neurological and smooth muscle disorders. Further in vivo studies are needed to characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Non-cell-based assays for N-phenethylbenzamide include iNOS inhibition assays using purified enzyme or cell lysates. The enzyme is incubated with arginine substrate in the presence of various concentrations of the compound, and NO production is measured using the Griess reaction. Antimicrobial susceptibility testing is performed using broth microdilution or agar diffusion methods to determine MICs against bacterial strains. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for N-phenethylbenzamide use RAW264.7 macrophage cells to assess inhibition of LPS-induced NO production. Cells are stimulated with LPS and treated with the compound at various concentrations, and NO production in culture supernatant is measured using the Griess reaction. For antimicrobial studies, bacterial cultures are treated with the compound and growth inhibition is measured. Cytotoxicity is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo studies of N-phenethylbenzamide are limited. Based on its biological activities, potential animal models include: carrageenan-induced paw edema models for anti-inflammatory evaluation; infection models for antimicrobial evaluation; and models of pain, inflammation, and cancer for evaluating other activities. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
N-Phenethylbenzamide has a molecular formula of C₁₅H₁₅NO and a molecular weight of 225.29 g/mol. Purity is ≥99.56%. It is an active compound extracted from Liriodendron tulipifera. It should be stored under recommended conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for N-phenethylbenzamide are limited. As a natural compound with anti-inflammatory and antimicrobial activities, it is generally considered to have low toxicity. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that N-phenylethylbenzamide has been found in Haplophyllum tuberculatum, and relevant data are available for reference.
N-Phenethylbenzamide is a secondary benzamide extracted from Liriodendron tulipifera. It inhibits LPS-induced NO production in RAW264.7 cells with an IC₅₀ of >50 μM and exhibits anti-inflammatory, analgesic, and anticancer properties. It also shows neuroprotective and spasmolytic activities and has demonstrated efficacy against MRSA and VRE. It can interact with various cellular pathways and is useful in drug development for pain, inflammation, and cancer. It is for research use only. |
| Molecular Formula |
C15H15NO
|
|---|---|
| Molecular Weight |
225.29
|
| Exact Mass |
196.956
|
| CAS # |
3278-14-6
|
| PubChem CID |
95083
|
| Appearance |
White to off-white solid
|
| Density |
1.088g/cm3
|
| Boiling Point |
439ºC at 760 mmHg
|
| Melting Point |
117-118 °C
|
| Flash Point |
264.3ºC
|
| Index of Refraction |
1.581
|
| LogP |
3.05
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
227
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CC=CC=C1)NCCC2=CC=CC=C2
|
| InChi Key |
DAVRGGJTJDTVQT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H15NO/c17-15(14-9-5-2-6-10-14)16-12-11-13-7-3-1-4-8-13/h1-10H,11-12H2,(H,16,17)
|
| Chemical Name |
N-(2-phenylethyl)benzamide
|
| Synonyms |
N-Phenethylbenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (221.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4387 mL | 22.1936 mL | 44.3872 mL | |
| 5 mM | 0.8877 mL | 4.4387 mL | 8.8774 mL | |
| 10 mM | 0.4439 mL | 2.2194 mL | 4.4387 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
